ALK-Abelló A/S

ALK-Abelló A/S, commonly known as ALK, is a global specialty pharmaceutical company based in Hørsholm, Denmark, dedicated to improving the lives of people living with allergies. With over a century of experience, the company's core mission is to help five million allergy sufferers by 2030 through continuous innovation and growth.

ALK specializes in allergy immunotherapy (AIT) products, offering a range of treatments including sublingual immunotherapy (SLIT) tablets for common allergens like grass pollen, ragweed pollen, and house dust mites, as well as sublingual drops and subcutaneous immunotherapy. The company also develops solutions for anaphylaxis, such as the nasal adrenaline spray EURneffy. ALK's scientific focus areas include respiratory allergies, food allergies, and anaphylaxis, serving patients and healthcare professionals across 46 markets worldwide, with significant presence in Europe and North America, and expanding into the Asia-Pacific region.

Led by President & CEO Peter Halling, ALK continues to advance its market position. Recent developments include the successful outcome of a Phase 2 trial for its peanut allergy tablet in April 2026. In the same month, its needle-free nasal adrenaline treatment, EURneffy, received approval in Canada for adults and children, and in the UAE, marking the region's first nasal adrenaline spray for severe allergic reactions. The company reported robust financial performance in its 2025 annual report, with 15% revenue growth and a 26% EBIT margin, underscoring its commitment to its "Allergy+" strategy aimed at strengthening leadership in allergy immunotherapy and establishing a prominent role in food allergy and anaphylaxis.